Search bioRxiv⌕ Search

Biology subjects

Toots, M.

Publications and source records attributed to Toots, M..

2 recordsLinked to original sources

Expressed therapeutic protein yields are predicted by transiently transfected mammalian cell population

Therapeutic proteins are currently at the hotspot of innovation in the pharmaceutical medicine. However, their industrial production is technically challenging and improved methods for transcriptional manipulation of mammalian industrial cell cultures are needed. In this work we show that some of the most frequently used lab scale transfection efficacy assays fail to predict performance in the protein production settings. We compare the efficacies of a number of transfection reagents using adherent and suspension mammalian cell cultures and assessment based on several assays that utilize reporter protein quantitation, transfected cell population and post-transfection viability of cells. We validate reporter assays for assessing transfection methods in the lab that predict protein production in industrial settings. We also demonstrate that cell penetrating peptide-based transfection achieve significantly higher protein yields compared to PEI and lipoplex methods in both CHO and HEK293 producer cell lines. Availability of fast lab scale screening methods allows future development of improved transfection methods for protein production. One such potentially effective transient transfection method is the CPP-based approach presented currently.

biochemistry↗

4'-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replication

The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and the elderly. We describe 4-fluorouridine (4-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and SARS-CoV-2 with high selectivity index in cells and well-differentiated human airway epithelia. Polymerase inhibition in in vitro RdRP assays established for RSV and SARS-CoV-2 revealed transcriptional pauses at positions i or i+3/4 post-incorporation. Once-daily oral treatment was highly efficacious at 5 mg/kg in RSV-infected mice or 20 mg/kg in ferrets infected with SARS-CoV-2 WA1/2020 or variant-of-concern (VoC) isolate CA/2020, initiated 24 or 12 hours after infection, respectively. These properties define 4-FlU as a broad-spectrum candidate for the treatment of RSV, SARS-CoV-2 and related RNA virus infections. One-Sentence Summary4-Fluorouridine is an orally available ribonucleoside analog that efficiently treats RSV and SARS-CoV-2 infections in vivo.

microbiology↗